TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Surui,Liu

第一单位： Department of Oncology, Jinan Central Hospital, Jinan, China.;Department of Oncology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.

作者： Surui,Liu ^[1] ; Jin,Yu ^[2] ; Hui,Zhang ^[3] ; Jie,Liu ^[2]

作者单位： Department of Oncology, Jinan Central Hospital, Jinan, China.;Department of Oncology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China. ^[1] Department of Oncology, Jinan Central Hospital, Jinan, China. ^[2] Department of Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. ^[3]

关键词 EGFR TP53 comutation non-small cell lung cancer (NSCLC)primary resistance treatment

DOI 10.3389/fonc.2022.860563

PMID 35444951

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交